Anti-Cancer Drug Backed: Cetus Corp.’s anti-cancer drug...
Anti-Cancer Drug Backed: Cetus Corp.’s anti-cancer drug Proleukin interleukin-2 has been recommended for approval by the European Economic Community’s committee for proprietary medicinal products. The drug is used in treatment of advanced kidney cancer. The role of the committee, which meets in Brussels on a regular basis, is to act as a centralized body for review of applications for approval of biotech and high-tech drugs and to issue an opinion regarding drug approval. The company said it also applied in November for marketing approval of Proleukin with the U.S. Food and Drug Administration.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.